drugset / Trial / NCT00428792

Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)

NCT00428792

Phase 3 Completed 150 enrolled Novartis
RandomizedCrossoverSingle-blindTreatment

Summary

This study evaluated the safety and clinical effect of treatment with methylphenidate under different breakfast conditions (minimal breakfast versus standard continental breakfast) in children with Attention-Deficit Hyperactivity Disorder (ADHD).

Timeline

Start
2007-04
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 20 mg Oral
Subject Methylphenidate Small molecule 40 mg Oral